Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:10:57.397Z.
Calculation as of: 2026-10-06T16:10:57.397Z.
Quote observation: 2026-10-06T16:07:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0d3cab615a00e4182867faf392a700f3c2ff11ca91232cb78ad2c83a49f3690
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Bone Biologics Corporation
Market Cap
$859930.00
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.04M
EBITDA Yield
N/A
TTM Avg
86.52%
3Y Avg
86.52%
5Y Avg
86.52%
Market Cap
$667373.00
EBITDA Yield
24.23%
TTM Avg
13.08%
3Y Avg
19.90%
5Y Avg
19.90%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bone Biologics Corporation (BBLG) | $859930.00 | N/A | N/A | N/A | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $858810.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $873967.00 | N/A | 0.07% | 0.06% | 0.06% |
| Decoy Therapeutics Inc. (DCOY)vs › | $845829.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $821563.00 | N/A | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $809925.00 | N/A | 4.73% | 14.60% | 25.10% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.04M | N/A | 86.52% | 86.52% | 86.52% |
| CDT Equity Inc. (CDT)vs › | $667373.00 | 24.23% | 13.08% | 19.90% | 19.90% |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
